These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38646375)

  • 1. Appearance and Prevalence of JN.1 SARS-CoV-2 Variant in India and Its Clinical Profile in the State of Maharashtra.
    Karyakarte RP; Das R; Rajmane MV; Dudhate S; Agarasen J; Pillai P; Chandankhede PM; Labhshetwar RS; Gadiyal Y; Kulkarni PP; Nizarudeen S; Yanamandra S; Taji N; Joshi S; Potdar V
    Cureus; 2024 Mar; 16(3):e56718. PubMed ID: 38646375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chasing SARS-CoV-2 XBB.1.16 Recombinant Lineage in India and the Clinical Profile of XBB.1.16 Cases in Maharashtra, India.
    Karyakarte RP; Das R; Rajmane MV; Dudhate S; Agarasen J; Pillai P; Chandankhede PM; Labhshetwar RS; Gadiyal Y; Kulkarni PP; Nizarudeen S; Joshi S; Karmodiya K; Potdar V
    Cureus; 2023 Jun; 15(6):e39816. PubMed ID: 37397651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected With Omicron Subvariants and the XBB Recombinant Variant.
    Karyakarte RP; Das R; Dudhate S; Agarasen J; Pillai P; Chandankhede PM; Labhshetwar RS; Gadiyal Y; Rajmane MV; Kulkarni PP; Nizarudeen S; Joshi S; Potdar V; Karmodiya K
    Cureus; 2023 Feb; 15(2):e35261. PubMed ID: 36968876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JN.1 variant in enduring COVID-19 pandemic: is it a variety of interest (VoI) or variety of concern (VoC)?
    Kamble P; Daulatabad V; Singhal A; Ahmed ZS; Choubey A; Bhargava S; John NA
    Horm Mol Biol Clin Investig; 2024 Jun; 45(2):49-53. PubMed ID: 38622986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Early and Preliminary Assessment of the Clinical Severity of the Emerging SARS-CoV-2 Omicron Variants in Maharashtra, India.
    Karyakarte RP; Das R; Taji N; Yanamandra S; Shende S; Joshi S; Karekar B; Bawale R; Tiwari R; Jadhav M; Sakalkar S; Chaudhari G; Rane S; Agarasen J; Pillai P; Dudhate S; Chandankhede P; Labhshetwar R; Gadiyal Y; Rajmane M; Mukade S; Kulkarni P
    Cureus; 2022 Nov; 14(11):e31352. PubMed ID: 36514661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unveiling the emergence of SARS-CoV-2 JN.1 sub-variant: Insights from the first cases at Charles Nicolle Hospital, Tunisia.
    Hamzaoui Z; Ferjani S; Kanzari L; Ben Ali R; Charaa L; Landolsi I; Medini I; Chammam S; Abid S; Ferjani A; Kebaier D; Fakhfakh A; Bouslah Z; Ben Sassi M; Trabelsi S; Boutiba-Ben Boubaker I
    Acta Microbiol Immunol Hung; 2024 Jul; 71(2):165-171. PubMed ID: 38717854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.
    Moustsen-Helms IR; Bager P; Larsen TG; Møller FT; Vestergaard LS; Rasmussen M; Hansen CH;
    Lancet Infect Dis; 2024 May; ():. PubMed ID: 38761806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents.
    Abul Y; Nugent C; Vishnepolskiy I; Wallace T; Dickerson E; Holland L; Esparza I; Winkis M; Wali KT; Chan PA; Baier RR; Recker A; Kaczynski M; Kamojjala S; Pralea A; Rice H; Osias O; Oyebanji OA; Olagunju O; Cao Y; Li CJ; Roederer A; Pfeifer WM; King CL; Bosch J; Nanda A; McNicoll L; Mujahid N; Raza S; Tyagi R; Wilson BM; White EM; Canaday DH; Gravenstein S; Balazs AB
    medRxiv; 2024 Mar; ():. PubMed ID: 38585784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring New COVID-19 Incertitude: JN.1 Variant- JN.1: The Queer Bird Among Omicron Sublineages.
    Ray SK; Mukherjee S
    Infect Disord Drug Targets; 2024 Jun; ():. PubMed ID: 38939989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity - IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024.
    Ma KC; Surie D; Lauring AS; Martin ET; Leis AM; Papalambros L; Gaglani M; Columbus C; Gottlieb RL; Ghamande S; Peltan ID; Brown SM; Ginde AA; Mohr NM; Gibbs KW; Hager DN; Saeed S; Prekker ME; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Khan A; Hough CL; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Kwon JH; Parikh B; Exline MC; Vaughn IA; Ramesh M; Safdar B; Mosier J; Harris ES; Shapiro NI; Felzer J; Zhu Y; Grijalva CG; Halasa N; Chappell JD; Womack KN; Rhoads JP; Baughman A; Swan SA; Johnson CA; Rice TW; Casey JD; Blair PW; Han JH; Ellington S; Lewis NM; Thornburg N; Paden CR; Atherton LJ; Self WH; Dawood FS; DeCuir J
    medRxiv; 2024 Jun; ():. PubMed ID: 38883802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage.
    Lewnard JA; Mahale P; Malden D; Hong V; Ackerson BK; Lewin BJ; Link-Gelles R; Feldstein LR; Lipsitch M; Tartof SY
    medRxiv; 2024 Apr; ():. PubMed ID: 38699313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omicron variants of SARS-CoV-2: Epidemiological and clinical insights from a tertiary care center in Saudi Arabia.
    Dubaie B; Aldayel A; Alwethinani S; Alhuthil R; Alhamlan F; Alghamdi S; Alsuhaibani M; Aljumaah S; AlYabes O; AlBanyan E; Al-Hajjar S
    J Infect Public Health; 2024 Jun; 17(6):961-966. PubMed ID: 38608457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of SARS-CoV-2 Omicron Variant JN.1 in Tamil Nadu, India - Clinical Characteristics and Novel Mutations.
    Selvavinayagam ST; Sankar S; Yong YK; Murugesan A; Suvaithenamudhan S; Hemashree K; Rajeshkumar M; Kumaresan A; Pandey RP; Shanmugam S; Arthydevi P; Kumar MS; Gopalan N; Kannan M; Cheedarla N; Tan HY; Zhang Y; Larsson M; Balakrishnan P; Velu V; Byrareddy SN; Shankar EM; Raju S
    medRxiv; 2024 Apr; ():. PubMed ID: 38699322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
    Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Bolland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
    Nat Commun; 2024 Mar; 15(1):2254. PubMed ID: 38480689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spatiotemporal dynamics and epidemiological impact of SARS-CoV-2 XBB lineage dissemination in Brazil in 2023.
    Arantes I; Gomes M; Ito K; Sarafim S; Gräf T; Miyajima F; Khouri R; de Carvalho FC; de Almeida WAF; Siqueira MM; Resende PC; Naveca FG; Bello G;
    Microbiol Spectr; 2024 Mar; 12(3):e0383123. PubMed ID: 38315011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omicron BA.2 lineage predominance in severe acute respiratory syndrome coronavirus 2 positive cases during the third wave in North India.
    Zaman K; Shete AM; Mishra SK; Kumar A; Reddy MM; Sahay RR; Yadav S; Majumdar T; Pandey AK; Dwivedi GR; Deval H; Singh R; Behera SP; Kumar N; Patil S; Kumar A; Dudhmal M; Joshi Y; Shukla A; Gawande P; Kavathekar A; Kumar N; Kumar V; Kumar K; Singh RS; Kumar M; Tiwari S; Verma A; Yadav PD; Kant R
    Front Med (Lausanne); 2022; 9():955930. PubMed ID: 36405589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
    Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Boland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; ; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
    bioRxiv; 2024 Feb; ():. PubMed ID: 38045308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Characterization of an Emerging SARS-CoV-2 Variant During the Early Second Wave of the SARS-CoV-2 Pandemic in Maharashtra, India.
    Karyakarte RP; Das R; Joshi S; Jayaram A; Yanamandra S; Shende S; Taji N; Rane S; Bawale R; Chaudhari GP; Karekar B; Sakalkar SR; Tiwari RG; Jadhav MG
    Cureus; 2023 Nov; 15(11):e48604. PubMed ID: 38090396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines.
    Chalkias S; McGhee N; Whatley JL; Essink B; Brosz A; Tomassini JE; Girard B; Edwards DK; Wu K; Nasir A; Lee D; Avena LE; Feng J; Deng W; Montefiori DC; Baden LR; Miller JM; Das R
    J Infect Dis; 2024 Feb; ():. PubMed ID: 38349280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation Analysis of SARS-CoV-2 Variants Isolated from Symptomatic Cases from Andhra Pradesh, India.
    Nagaraja M; Sireesha K; Srikar A; Sudheer Kumar K; Mohan A; Vengamma B; Tirumala C; Verma A; Kalawat U
    Viruses; 2023 Jul; 15(8):. PubMed ID: 37631999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.